Merrimack College

Merrimack ScholarWorks
Biology Faculty Publications

Biology

8-2006

MyoD Synergizes with the E-protein HEB Beta to Induce Myogenic
Differentiation
Maura H. Parker
Robert L.S. Perry
Melanie C. Fauteux
Charlotte A. Berkes
Merrimack College, berkesc@merrimack.edu

Michael A. Rudnicki

Follow this and additional works at: https://scholarworks.merrimack.edu/bio_facpubs
Part of the Cell Biology Commons, and the Molecular Biology Commons

Repository Citation
Parker, M. H., Perry, R. L., Fauteux, M. C., Berkes, C. A., & Rudnicki, M. A. (2006). MyoD Synergizes with the
E-protein HEB Beta to Induce Myogenic Differentiation. Molecular and Cellular Biology, 26(15), 5771-5783.
Available at: https://scholarworks.merrimack.edu/bio_facpubs/3

This Article - Open Access is brought to you for free and open access by the Biology at Merrimack ScholarWorks. It
has been accepted for inclusion in Biology Faculty Publications by an authorized administrator of Merrimack
ScholarWorks. For more information, please contact scholarworks@merrimack.edu.

MOLECULAR AND CELLULAR BIOLOGY, Aug. 2006, p. 5771–5783
0270-7306/06/$08.00⫹0 doi:10.1128/MCB.02404-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Vol. 26, No. 15

MyoD Synergizes with the E-Protein HEB␤
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The MyoD family of basic helix-loop-helix transcription factors function as heterodimers with members of
the E-protein family to induce myogenic gene activation. The E-protein HEB is alternatively spliced to generate
␣ and ␤ isoforms. While the function of these molecules has been studied in other cell types, questions persist
regarding the molecular functions of HEB proteins in skeletal muscle. Our data demonstrate that HEB␣
expression remains unchanged in both myoblasts and myotubes, whereas HEB␤ is upregulated during the
early phases of terminal differentiation. Upon induction of differentiation, a MyoD-HEB␤ complex bound the
E1 E-box of the myogenin promoter leading to transcriptional activation. Importantly, forced expression of
HEB␤ with MyoD synergistically lead to precocious myogenin expression in proliferating myoblasts. However,
after differentiation, HEB␣ and HEB␤ synergized with myogenin, but not MyoD, to activate the myogenin
promoter. Specific knockdown of HEB␤ by small interfering RNA in myoblasts blocked differentiation and
inhibited induction of myogenin transcription. Therefore, HEB␣ and HEB␤ play novel and central roles in
orchestrating the regulation of myogenic factor activity through myogenic differentiation.
factor and/or the presence of other factors that may potentiate
or inhibit dimerization. Therefore, the ability of bHLH factors
to homo- or heterodimerize in a variety of combinations raises
the hypothesis that regulation of dimer formation is essential
for control of muscle-specific gene expression.
The role of E2A in myogenesis was first postulated upon
finding that MyoD was able to heterodimerize with E12 and
E47 in vitro (34, 35). Moreover, cotransfection of MyoD and
E47 is required for E-box transcriptional activity in COS cells
(28). However, gene-targeting experiments have indicated that
E12 and E47 are not essential for skeletal muscle formation or
function (62). We previously demonstrated that C2C12 murine
myoblasts and 10T1/2 fibroblasts, which are nonmyogenic yet
amenable to myogenic conversion upon expression of MyoD,
do not express E12 or E47 protein (43). Conway and colleagues confirmed this result by demonstrating that neither
E12 nor E47 is expressed in C2C12 myoblasts or adult skeletal
muscle tissue (9).
HEB protein, however, is expressed in 10T1/2 fibroblasts
and C2C12 myoblasts (43). HEB is highly expressed in skeletal
muscle as well as in the thymus and in B cells and is able to
bind to E-boxes in a manner similar to other E-protein family
members (21). During embryonic development, HEB is widely
expressed in the limb buds, somites, and proliferating neuroblasts. Importantly, expression is highest during the initial
stages of differentiation and decreases once cellular differentiation has been established (37). Mice lacking HEB die at 2
weeks of age; however, the characterization of muscle development has yet to be reported (61).
Alternative splicing of the HEB gene generates two isoforms
termed HEB␣ and HEB␤. The HEB␤ isoform is distinguished

Basic helix-loop-helix (bHLH)-containing transcription factors play an important role in directing the development of a
variety of cellular lineages by regulating expression of a restricted set of tissue-specific target genes (57). The myogenic
regulatory factors (MRFs) are a group of muscle-specific
bHLH transcription factors, consisting of MyoD, Myf5, myogenin, and MRF4, that control skeletal muscle development (41).
Genetic and expression analyses indicate that Myf5 and MyoD
act as determination factors that specify muscle progenitor cell
identity. Although expression of MyoD or Myf5 commits a cell
to the myogenic lineage, expression of MyoD is more effective
at initiating differentiation. Myogenin is induced upon differentiation and plays an important role in activating the differentiation program. MRF4 appears to have a role as a determination factor in a subset of myocytes in the early somite and
as a differentiation factor in later muscle fibers (24).
Transcription of muscle-specific genes is dependent upon
dimer interactions between MRFs and the more ubiquitously
expressed E-proteins, a process mediated by the helix-loophelix motif. The E-protein family includes the E2A gene products (E12/E47), the E2-2 gene products (ITF-2A and 2B), and
the HEB gene products (HEB␣ and HEB␤). Dimerization is
dependent upon the relative abundance of each transcription
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by insertion of a 24-amino-acid ankyrin-like motif, resulting
from inclusion of a 72-bp alternate exon (27). HEB␤ differs
from HEB␣ in DNA binding affinity as well as homo- and
heterodimerization properties. Prediction of the domain structure of HEB, based on studies of E12 and E47, reveals that this
motif intersects the second putative activation domain (AD2)
and may alter one face of the ␣-helix present in this domain
(18, 32, 33).
To determine if HEB plays a role in specifically regulating
MRF transcriptional activity, we asked if HEB␣ and HEB␤
show evidence of distinct transcriptional partner preferences
or exhibit unique regulatory properties during skeletal muscle
differentiation. Our experiments establish an essential and
novel role for HEB␤ in regulating the switch from myogenin
repression to myogenin activation as an immediate-early step in
the myogenic differentiation program. We demonstrate that
HEB␣ and HEB␤ specifically regulate MyoD transcriptional
activity during early differentiation and myogenin activity later
in differentiation. Furthermore, we show that HEB␣ and
HEB␤ function uniquely on different promoters and, more
importantly, function distinctly on the same promoter. Importantly, we demonstrate that specific loss of HEB␤ expression in
myoblasts inhibited myogenin expression and fusion of myoblasts during differentiation. Together, the data establishe a
novel mechanism by which MRF/HEB complexes and isoform
switching are critical to activating the terminally differentiated
phenotype during skeletal muscle development.
MATERIALS AND METHODS
Cell culture and transfections. C3H10T1/2 fibroblasts (CCL-226; ATCC) and
C2C12 myoblasts (CRL-1772; ATCC) were maintained in growth medium (GM)
consisting of Dulbecco’s modified eagle medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS; Gemini Bioscience), 0.1 units/ml of
penicillin, and 0.1 g/ml of streptomycin (1⫻; Invitrogen). Transfections were
performed using the calcium phosphate method as previously described (43).
Briefly, 1 day prior to transfections, cells were plated at 3.5 ⫻ 104 cells per 60-mm
dish (Falcon) for 10T1/2 cells, or 2.5 ⫻ 104 cells per 60-mm dish for C2C12 cells.
Cells were incubated with the calcium phosphate precipitate for 16 h, washed
twice with phosphate-buffered saline (PBS) and refed with GM. Twenty-four
hours after refeeding, cells were either harvested (GM) or washed once with PBS
and refed with differentiation medium (DM; DMEM plus 2% horse serum
[Invitrogen] and penicillin/streptomycin) and cultured for an additional 48 h.
Transfections were assayed for efficiency by inclusion of a plasmid expressing
either ␤-galactosidase or green fluorescent protein.
Primary myoblasts were isolated as described previously (46) and maintained
in Ham’s F-10 medium (Invitrogen) supplemented with 20% FBS, 2⫻ penicillin/
streptomycin, and 12.5 ng/ml basic fibroblast growth factor (Invitrogen). Primary
myoblasts were induced to differentiate by washing the cells once with PBS and
refeeding them with DMEM supplemented with 5% horse serum and 2⫻ penicillin/streptomycin.
Plasmids. Plasmids expressing MyoD, Myf5, or myogenin were constructed in
pEMSV as previously described (13). Expression plasmids encoding HEB␣ and
HEB␤ were constructed by reverse transcription (RT)-PCR using RNA from
differentiating primary myoblasts as a template and primers specific for the N
and C termini of murine HEB: F1, 5⬘-ATGAATCCCCAGCAGCAGCGCAT
G-3⬘; R1, 5⬘-CCATGGTCAGATGACCCATAGGGTTGGT-3⬘.
The PCR products were cloned into the EcoRI site of pEMSV. The plasmids
encoding ITF-2A and ITF-2B were kind gifts from Ilona Skerjanc. The E12
expression plasmid was a kind gift from Lauren Snider, and the E47 expression
plasmid was a kind gift from Cornelius Murre. The 4R-Luc plasmid was constructed by cloning the BamHI fragment from 4RtkCAT (55) into the BglII site
of the pGL3 promoter reporter vector (Promega). The BamHI fragment from
MLC-CAT (14) was also cloned into the BglII site of this vector to obtain the
MLC-Luc. Myogenin-luciferase (Mgn-Luc) and the E-box mutants were constructed as previously described (5). Plasmids encoding deletion mutants of
MyoD and the activated mutant of MEK1 were previously described (43). Vec-
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tors lacking cDNA inserts or promoter elements were used as controls in the
transfections.
RNA isolation. C2C12 myoblasts and 10T1/2 fibroblasts were grown to approximately 85 to 90% confluence in 60-mm dishes and either harvested as a GM
sample or washed once with PBS and refed with DM. The cells were then
harvested at various time points after being refed with DM. RNA was isolated
according to manufacturer’s instructions using the RNeasy mini kit (QIAGEN).
The RNA was quantitated, and 5 g was run on a formaldehyde gel to ensure
integrity.
RT-PCR. RT-PCR was carried out using the RNA PCR core kit (Applied
Biosystems). Briefly, 1 g of RNA was reverse transcribed for 1 h at 42°C using
random hexamers. One-eighth of the reaction mixture was used in a PCR (20
cycles) with primers specific for ␤-actin (forward, 5⬘-TGAGACCTTCAACACC
CCAG-3⬘; reverse, 5⬘-GAGCCAGAGCAGTAATCTCC-3⬘) to ensure proper
quantitation of the RNA. One-fourth of the reaction mixture was used in a PCR
(30 cycles) with primers specific for HEB or E2A: HEB forward, 5⬘-GATCTC
CTTCACCTCTCACAG-3⬘; HEB reverse, 5⬘-TAGTAGGCAGACTGGTAGA
AG-3⬘. The primers for E2A were specific for the bHLH: E12 forward, 5⬘-CC
AGACGAGGACGAGGACGAC-3⬘; E47 forward, 5⬘-AGTACAGATGAGGT
GCTGTCC-3⬘; E2A reverse, 5⬘-ACCACGCCAGACACCTTCTCC-3⬘. The
PCRs were optimized to ensure that amplification was within the linear range.
Protein extraction. Cells were washed twice with PBS, scraped with NP-40 lysis
buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1% NP-40, 1.5 mM MgCl2, 1
mM dithiothreitol, 10 mM NaF, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM
Na3VO4, 1 g/ml aprotinin, 1 g/ml pepstatin, and 1 g/ml leupeptin), and
transferred to a 1.5-ml Eppendorf tube. The cells were incubated on ice for 30 to
45 min with periodic vortexing, and the lysates cleared by centrifugation. Protein
concentration was determined using the modified Bradford assay (Bio-Rad)
using bovine serum albumin as a standard.
Immunoblotting and antibodies. Western blot analysis was performed as described previously (43). The antibodies used were anti-HEB (A-20; Santa Cruz),
anti-MyoD (C-20; Santa Cruz), anti-myogenin (F5D; Developmental Studies
Hybridoma Bank), anti-Myf5 (C-20; Santa Cruz), anti-E2A (V-18; Santa Cruz),
anti-tubulin (DM1A; Sigma), and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Ambion). For immunoblotting, all antibodies were used according to the manufacturer’s instructions, and anti-myogenin was used at 1:10
(hybridoma supernatant). Anti-mouse and anti-rabbit secondary antibodies were
used at 1:2,000 (Bio-Rad) and were detected using enhanced chemiluminescence
(Amersham-Pharmacia).
Chromatin immunoprecipitation assays. For each immunoprecipitation, the
protein and DNA in approximately 1 ⫻ 106 C2C12 myoblasts/myotubes or 1.5 ⫻
106 transfected 10T1/2 fibroblasts were cross-linked by the addition of formaldehyde directly to the culture medium to a final concentration of 1% and
incubated for 10 min at 37°C. The cells were washed twice with ice-cold PBS
containing protease inhibitors (PBS⫹; 1 mM phenylmethylsulfonyl fluoride, 1
g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin A). The cells were lysed
with 200 l of sodium dodecyl sulfate lysis buffer (Upstate), and the samples
from the same cell type were pooled and redivided so each immunoprecipitation
represented the same amount of starting material. The cross-linked proteinDNA complexes were isolated according to the manufacturer’s instructions
(chromatin immunoprecipitation [ChIP] assay kit; Upstate). For input DNA, 50
l of sample was removed prior to the immunoprecipitation (IP), the cross-links
were reversed as instructed in the kit protocol, and the DNA was purified using
the PCR purification kit (QIAGEN). The amount of input DNA was quantitated
using the PicoGreen double-stranded DNA quantitation kit (Molecular Probes).
The antibodies used to immunoprecipitate the complexes were all supplied by
Santa Cruz (anti-MyoD [C-20], anti-HEB [A-20], anti-Myf5 [C-20], and antimyogenin [M-225]) and used at 1 g per IP. After the IP, the immunoprecipitated complexes were washed according to the manufacturer’s protocol, the
cross-links were reversed, and the DNA was purified.
Input DNA (8.2 ng) from 10T1/2 samples and 1.2 ng of input DNA from
C2C12 samples were used in a 25-cycle PCR. The amount of immunoprecipitated DNA used for each PCR was determined based on the concentration of
input DNA. PCRs were optimized to ensure that amplification was within the
linear range, and the primers used were previously described (3).
Reporter assays. Transfected cells were washed twice with PBS and scraped
with 1⫻ reporter lysis buffer (Promega). The cells were incubated on ice for 30
min with periodic vortexing, followed by one round of freeze-thaw lysis. The
extracts were centrifuged and the supernatant transferred to a new tube. Luciferase activity was assayed using 10 to 15 l of extract and the luciferase assay
system (Promega). The protein concentration was determined using the modified
Bradford assay (Bio-Rad), and the relative light units (RLUs) from the luciferase
assay were normalized using protein concentration. Relative activity was deter-
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mined by setting the RLUs for the reporter vector-alone sample as 1. Synergy is
defined as
synergy ⫽

RLUs(MRF ⫹ HEB)
RLUs(MRF) ⫹ RLUs(HEB)

where the RLUs represent luciferase activity normalized to protein concentration.
siRNA. HEB target sequences were chosen from a group of possible sequences
from the small interfering RNA (siRNA) target finder website (Ambion). The
following DNA oligonucleotides were synthesized (Alpha DNA): no. 15, 5⬘-AAT
GAC AGT CGA TTA GGA ACC CCTGTCTC-3⬘ (antisense), 5⬘-AA GGT
TCC TAA TCG ACT GTC A CCTGTCTC-3⬘ (sense); no. 36, 5⬘-AAT CTC
CTA GTT ACC CAT CTC CCTGTCTC-3⬘ (antisense), 5⬘-AA GAG ATG GGT
AAC TAG GAG A CCTGTCTC-3⬘ (sense); no. 67, 5⬘-AAT GCA TCA ATT
GGA AAC CTC CCTGTCTC-3⬘ (antisense), 5⬘-AA GAG GTT TCC AAT
TGA TGC A CCTGTCTC-3⬘ (sense); no. 60 5⬘-AAC TTC ACG AGC ATT
TGC AAG CCTGTCTC-3⬘ (antisense), 5⬘-AA CTT GCA AAT GCT CGT
GAA G CCTGTCTC-3⬘ (sense). siRNA molecules were constructed using the
Silencer siRNA construction kit (Ambion). GAPDH siRNA was synthesized
using DNA oligonucleotides provided by Ambion and served as a positive control. The siRNA was labeled with Cy3 using the Silencer siRNA labeling kit
(Ambion) to permit visualization of transfected cells.
C2C12 myoblasts were plated at 1 ⫻ 104 cells per 35-mm plate. The following
day, the cells were transfected with 18.75 pmol of siRNA using Oligofectamine
(Invitrogen) and cultured for 2 days. The cells were washed once with PBS, refed
with DM without penicillin/streptomycin, and cultured for 48 or 96 h.
Immunocytochemistry. Cells were fixed with 4% paraformaldehyde–PBS for 5
min at room temperature, and the fixation was stopped with 100 mM glycine–
PBS for 5 min. The cells were washed three times with PBS and permeabilized
in 0.3% Triton X-100–PBS for 5 min, followed by another three washes in PBS.
The cells were blocked in 10% goat serum–PBS for 1 h, followed by incubation
for 1 h with primary antibody (F5D [anti-myogenin] or MF20 [anti-myosin heavy
chain], 1:20 in 10% goat serum–PBS; Developmental Studies Hybridoma Bank).
The cells were then washed three times in PBS and incubated with fluorescein
isothiocyanate-conjugated anti-mouse secondary (1:200 in 10% goat serum–PBS;
Chemicon) for 1 h. The cells were washed three times in PBS, and nuclei were
stained with 4⬘,6⬘-diamidino-2-phenylindole (DAPI; 0.25 g/ml in PBS) for 5
min. The cells were washed once in PBS and mounted with fluorescence mounting medium (DAKO).

RESULTS
Induction of HEB␤ during myogenic differentiation. To examine the expression pattern of HEB and E2A during myogenic differentiation, Western blots were performed using extracts from C2C12 myoblasts, primary murine myoblasts, and
10T1/2 fibroblasts. C2C12 myoblasts and primary myoblasts
were grown to 85 to 90% confluence and either harvested for
protein isolation (GM; DMEM plus 10% FBS) or switched to
differentiation medium (DM; DMEM plus 2% horse serum).
The cells were harvested and the protein isolated daily over a
4-day period after stimulation with DM. Western blot analysis
of protein extracts using an antibody that recognized both
isoforms of HEB demonstrated that HEB was abundantly expressed in all three cell types (Fig. 1A). However, expression of
HEB protein was almost undetectable by 4 days after the onset
of differentiation in myoblasts, suggesting that stability of HEB
protein, or translation of the message, is regulated during
myogenic differentiation (Fig. 1A).
Western analysis revealed readily detectable E12 and E47
protein in tibialis anterior muscle (Fig. 1A, lane 1), transfected
fibroblasts (Fig. 1A, lanes 2 and 3), and adult mouse mammary
tissue (not shown). Strikingly, expression of E12 and E47 was
below the limit of detection in C2C12 myoblasts, primary myoblasts, and 10T1/2 fibroblasts (Fig. 1A, lanes 4 to 14). Therefore, the low abundance of E12 and E47 and high expression of

FIG. 1. HEB expression is highly regulated in proliferating and
differentiating myoblasts. (A) Western analysis of HEB and E2A expression reveals abundant HEB protein but no detectable E2A protein
in myoblasts and fibroblasts. (B) RNA was isolated from a differentiation time course of C2C12 myoblasts and 10T1/2 fibroblasts and
analyzed by RT-PCR. HEB␣ was expressed under both growth and
differentiation conditions in C2C12 cells, whereas HEB␤ was induced
upon differentiation. (C) RT-PCR detection of E12 and E47 mRNAs
in C2C12 and 10T1/2 cells. ␣-HEB, anti-HEB; ␣-E2A, anti-E2A; TA,
tibialis anterior muscle.

HEB proteins suggested that HEB is a significant transcriptional partner of the MyoD family of bHLH factors in myogenic cells.
To investigate the expression pattern of the two isoforms of
HEB in myogenic differentiation, RT-PCR was performed using RNA isolated from a differentiation time course of C2C12
myoblasts and 10T1/2 fibroblasts (Fig. 1B). C2C12 myoblasts
and 10T1/2 fibroblasts were grown to 85 to 90% confluence
and either harvested for RNA isolation (GM; DMEM plus
10% FBS) or switched to differentiation medium (DM;
DMEM plus 2% horse serum). The cells were harvested and
the RNA isolated daily over a 4-day period after stimulation
with DM.
To distinguish HEB␣ from HEB␤, PCR primers were designed that flanked the region surrounding the 72-bp ankyrinlike motif. RT-PCR analysis indicated that expression of
HEB␣ mRNA remained constant throughout both proliferation and differentiation in C2C12 myoblasts (Fig. 1B) and primary
myoblasts (not shown). By contrast, expression of HEB␤ was
induced upon differentiation with increased expression evident as
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FIG. 2. HEB binds muscle-specific promoters. ChIP revealed that
binding of HEB to the myogenin promoter and MLC enhancer increased markedly after differentiation. Amylase was amplified as a
control for specificity, and input DNA was amplified with each primer
set to ensure proper DNA quantitation. ␣-HEB, anti-HEB; ␣-MyoD,
anti-MyoD; ␣-Myf5, anti-Myf5; ␣-myogenin, antimyogenin.

differentiation proceeded (Fig. 1B). Notably, 10T1/2 fibroblasts
displayed no modulation in HEB isoform expression in highversus low-mitogen conditions or upon expression of MyoD (Fig.
1B; data not shown). Furthermore, levels of E12 and E47
mRNAs, as well as ITF-2A and ITF-2B mRNAs, remained unaltered in myoblasts through differentiation or in 10T1/2 fibroblasts after serum withdrawal (Fig. 1C; data not shown). Thus, the
absence of HEB␤ in proliferating myoblasts and its upregulation
during myogenic differentiation is consistent with a differentiation-specific role for HEB␤.
HEB regulates binding of MyoD to muscle-specific promoters. To determine if HEB is associated with promoters of
myogenicity-specific genes, ChIP assays were performed using
either proliferating or differentiating C2C12 myoblasts (Fig. 2).
Prior to the immunoprecipitation, a small volume of the extract from each sample was removed, the cross-links reversed,
and the DNA purified. This “input” DNA was carefully quantitated, and the amount of IP DNA used in each PCR was
determined by normalizing it to the amount of input DNA for
each immunoprecipitation. This was to ensure that the amount
of DNA used in each IP PCR reflected the same amount of
starting material. PCR amplification of the IP DNA was undertaken with primers specific for the myogenin promoter and
the MLC enhancer; primers specific for the amylase promoter
served as a negative control (Fig. 2, lanes 1 to 8). The input
DNA was also amplified with the same primers to ensure
accurate quantitation (Fig. 2, lanes 9 to 16).
In proliferating C2C12 myoblasts, both a HEB-specific antibody and a MyoD-specific antibody coimmunoprecipitated
DNA corresponding to the myogenin promoter and the MLC
enhancer but not the amylase promoter (Fig. 2, lanes 1 and 2).
However, binding of MyoD and HEB to the myogenin and
MLC enhancer promoter appeared minimal, even though both
MyoD and HEB were expressed in proliferating myoblasts
(data not shown). Myf5, on the other hand, is associated with
the MLC enhancer during proliferation but is not associated
with the myogenin promoter (Fig. 2, lane 3). A band corresponding to the MLC enhancer appears in the PCR amplification of the anti-myogenin ChIP DNA, but it is not enriched
for relative to the amylase-negative control, indicating that
myogenin is not associated with the enhancer in proliferation
(Fig. 2, lane 4). This is consistent with myogenin expression
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being restricted to differentiating C2C12 myoblasts (data not
shown).
After 2 days in differentiation medium, MyoD, myogenin,
and HEB were all associated with the myogenin promoter, yet
Myf5 was conspicuously absent (Fig. 2A, lanes 5 to 8). In a
similar manner, binding of MyoD, myogenin, and HEB to the
MLC enhancer was enhanced during differentiation relative to
proliferation (Fig. 2, lanes 5, 6, and 8). This was expected since
both myogenin and MLC are expressed exclusively during differentiation. Interestingly, Myf5 remained associated with the
MLC enhancer after 2 days in differentiation medium (Fig. 2,
lane 7). Neither the myogenin promoter nor the MLC enhancer
could be amplified from anti-E12/E47 ChIP DNA (data not
shown). These findings indicate that HEB binds to myogenic
E-boxes directly or indirectly in association with MyoD or
myogenin.
HEB␣ and HEB␤ differentially synergize with MyoD and
myogenin in a differentiation-specific manner. To study the
role of HEB in transcriptional activation, the mouse cDNAs
for both HEB␣ and HEB␤ were cloned by RT-PCR using
mRNA isolated from differentiating wild-type primary myoblasts. The full-length cDNAs were cloned into the EMSV
vector, the same vector from which the MRFs were expressed.
MRF transcriptional activity was assessed using reporter vectors containing either a portion of the murine myogenin promoter (Mgn-Luc) or rat myosin light chain enhancer (MLCLuc).
To determine the effect of each HEB isoform on each MRF,
10T1/2 fibroblasts were transfected with each reporter vector individually and one of EMSV-MyoD, -Myf5, -myogenin, or EMSV
control in addition to EMSV-HEB␣, EMSV-HEB␤, or EMSV
alone. To ensure similar transfection efficiency, cells were
transfected with a plasmid expressing lacZ under control of the
simian virus 40 promoter in addition to each combination of
plasmids indicated in Fig. 3. The cells were fixed, and examination of lacZ expression using 5-bromo-4-chloro-3-indolyl-␤D-galactopyranoside (X-Gal) demonstrated that the transfection efficiency was similar in all transfection conditions (data
not shown). Moreover, each relative activation value, or synergy value, represents the average of results from 9 or 12
samples from 3 or 4 different experiments, and the error bars
represent the standard deviations. In proliferation conditions
(GM), both HEB␣ and HEB␤ increased the activity of MyoD
on MLC-Luc but not Myf5 or myogenin activity (Fig. 3A, GM,
Fold Activation panel). In differentiation conditions (DM),
only the activity of myogenin was increased, and this was done
specifically through HEB␣ (Fig. 3A, DM, Fold Activation
panel).
A potential complication was that two transcription factors,
both capable of binding to the E-box sequence, were being
assayed. Therefore, to determine if the increase in activity was
additive (each transcription factor acting separately to increase
activity) or synergistic (the two factors acting cooperatively to
increase activity), a value, designated as “synergy” was calculated (32). If the value for synergy was 1, or close to 1, then
HEB and the MRF were deemed to be activating expression of
the reporter independently of each other. If the value was
significantly greater than 1, then the two transcription factors
were considered to have functioned cooperatively to activate
expression of the reporter (see Materials and Methods for
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FIG. 3. HEB-dependent increase in MRF activity is synergistic and multifaceted. (A) 10T1/2 fibroblasts were transfected with the MLC-Luc
reporter plasmid, plasmids expressing MyoD, Myf5, or myogenin, and either HEB␣ or HEB␤ expression plasmids. The panels on the left represent
relative activation. The activity of the MLC-Luc reporter plasmid alone was arbitrarily set at 1, and the activity in the presence of the effectors was
determined relative to this value (fold activation). The bars represent the mean relative activation, and the error bars represent standard deviations
(n ⫽ 9). The panels on the right represent synergy (see Materials and Methods). The horizontal line represents the value at which the two effectors
function independently or additively. The bars represent the mean synergy value, and the error bars represent standard deviations (n ⫽ 9). (B) The
same transfection as for panel A but with the Mgn-Luc reporter plasmid.

mathematical formula for synergy). The important distinction
is that synergy quantitatively represents the ability of two transcription factors to increase transcriptional activation of a reporter as partners in a complex or dimer, whereas relative
activation simply reflects the increase in activity resulting from
the activity of transcription factors that may or may not function cooperatively.
Coexpression of HEB␣ and MyoD increased activity of the
MLC enhancer more than threefold (synergy value) relative to
the activity of the enhancer in the presence of MyoD and
HEB␣ individually (Fig. 3A, GM, Synergy panel). HEB␤ also

acted synergistically with MyoD in proliferation conditions to
activate the MLC enhancer fourfold higher relative to each
factor functioning individually (Fig. 3A, GM, Synergy panel).
Although the cells were maintained in growth medium, they
initiated differentiation, as indicated by expression of endogenous myogenin (Fig. 4A, lanes 4 to 6). This suggested that the
increase in activity is representative of the initial stages of
differentiation rather than a true proliferative response.
This also suggests that the increase in activity may also be
due to HEB in complex with myogenin. However, neither
HEB␣ nor HEB␤ synergistically activated the MLC enhancer
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FIG. 4. HEB␤ enhances MyoD-mediated expression of endogenous
myogenin. (A) 10T1/2 fibroblasts were transfected as indicated and maintained in growth medium. Protein was isolated, and 25 g was analyzed by
Western blotting with the indicated antibodies. The expression of tubulin
was monitored as a control for protein quantitation. (B) The same transfection and Western blots as for panel A, but protein was isolated from
cells induced to differentiate for 2 days after transfection. (C) The same
transfection as for panels A and B, but RNA was isolated and analyzed by
RT-PCR. Transfection of HEB␣ specifically increases levels of HEB␣,
and transfection of HEB␤ specifically increases levels of HEB␤. ␣-MyoD,
anti-MyoD; ␣-Myf5, anti-Myf5; ␣-myogenin, antimyogenin; ␣-HEB,
anti-HEB; ␣-tubulin, antitubulin.
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in the presence of myogenin in GM (Fig. 3A, GM, Synergy
panel). Moreover, after 2 days in differentiation medium,
HEB␣ specifically synergized with myogenin and not MyoD to
activate the MLC enhancer (Fig. 3A, DM, Synergy panel). This
corresponded with the results observed in C2C12 myoblasts in
which only HEB␣ activated the MLC enhancer (data not
shown).
The activity of the myogenin promoter (Mgn-Luc) was regulated differently. HEB␤ specifically and synergistically activated the myogenin promoter in association with MyoD during
the initial stage of differentiation (Fig. 3B, GM, Synergy
panel). HEB␣ was unable to synergize with any of the MRFs
to activate Mgn-Luc. However, in later differentiation, both
HEB␣ and HEB␤ synergized with myogenin and not MyoD to
activate the myogenin promoter (Fig. 3B, DM, Synergy panel).
Given that HEB␤ expression was restricted to differentiating
myoblasts (Fig. 1B), these data strongly suggest that HEB␤
plays a role in the initiation of myogenic differentiation by
regulating expression of myogenin.
To further validate the data obtained using reporter vector
assays, we exogenously expressed the MRFs in 10T1/2 cells
either alone or with HEB␣ or HEB␤. In agreement with the
reporter vector assay results, HEB␤ was able to cooperate with
MyoD to enhance expression of endogenous myogenin to a
greater extent than HEB␣ (Fig. 4A, lanes 4 to 6). This was not
the result of increased MyoD or Myf5 expression, as MyoD
levels remained constant and Myf5 was undetectable in 10T1/2
cells transfected with MyoD. In addition, transfection with
Myf5 did not induce expression of myogenin in GM, even when
coexpressed with HEB isoforms (Fig. 5A, lanes 7 to 9). This is
consistent with the ChIP data, in which Myf5 did not bind the
myogenin promoter in vivo (Fig. 2A).
Consistent with the transfection data, myogenin-mediated
expression of myogenin in serum-starved 10T1/2 fibroblasts
was enhanced in the presence of exogenous HEB␣ and HEB␤
(Fig. 5B, lanes 4 to 6 and 10 to 12). This was not the result of
myogenin-induced expression of endogenous MyoD, as MyoD
was undetectable by Western blotting (Fig. 4B, lanes 10 to 12).
In addition, it was not the result of a HEB-mediated increase
in the activity of the MSV long terminal repeat, since the
expression of EMSV-MyoD and EMSV-Myf5 were not altered
in the presence of either HEB␣ or HEB␤.
Surprisingly, the level of HEB protein remained constant
even after transfection with plasmids encoding HEB␣ or
HEB␤. Given that the antibody recognizes both isoforms of
HEB, we sought to determine if the level of each isoform was
altered after transfection. 10T1/2 cells were transfected as indicated on Fig. 4C, and RNA was isolated from cells maintained in GM or induced to differentiate for 2 days (in DM)
(Fig. 4C). RT-PCR analysis demonstrated that exogenous expression of HEB␣ resulted in a predominance of the HEB␣
isoform and exogenous expression of HEB␤ resulted in a predominance of the HEB␤ isoform in all transfection conditions.
Taken together, these data reveal a hitherto unknown role for
HEB␤ in directing transcription during initiation of myogenic
differentiation.
Binding to the E1 E-box in the myogenin promoter by MyoDHEB␤ regulates induction of transcription during differentiation. The observation that HEB␣ and HEB␤ are able to
function in unique ways on the myogenin promoter suggested
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FIG. 5. MyoD activity on the myogenin promoter is E1 E-box specific. (A) Schematic diagram of the E-boxes in the Mgn-Luc reporter
vector and the mutant reporter vectors in which the E1 E-box has been
mutated (Mgn-LucE1mut), the E2 E-box has been deleted (MgnLucDE2), or both (Mgn-LucE1mutDE2). (B) Activity of Mgn-Luc in
transfected 10T1/2 fibroblasts. Cells were transfected with either
EMSV control, MyoD, HEB␣, or HEB␤ in addition to each of the
reporter plasmids indicated. The cells were maintained in growth medium, harvested, and assayed for luciferase activity. The bars represent
the mean activation relative to the control, and the error bars represent standard deviations (n ⫽ 3). (C) Synergy between MyoD and
HEB isoforms in the activation of Mgn-Luc in transfected 10T1/2
fibroblasts. Cells were transfected with combinations of MyoD and
HEB␣ or MyoD and HEB␤. The horizontal line represents the value
at which the two effectors function in an additive manner. The bars
represent the mean synergy values, and the error bars represent standard deviations (n ⫽ 3).

the possibility that specific complexes are being recruited to
discrete E-boxes. The 224-bp minimal myogenin promoter required to recapitulate myogenin expression in vivo contains
two consensus E-box sequences, E1 (CAGTTG) and E2 (CA
CATG) (Fig. 5A). To determine which complex is regulated by
HEB, reporter vectors, in which the E1 and E2 E-boxes are
selectively mutated, were employed.
Mutation of the E1 E-box (Mgn-LucE1mut) or deletion of
the E2 box (Mgn-Luc⌬E2) decreased MyoD-mediated activa-
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tion of the myogenin promoter during early differentiation (Fig.
5B). Moreover, the double mutant reporter vector (MgnLucE1mut/⌬E2) was completely unresponsive to MyoD, demonstrating the importance of these two canonical E-boxes in
MyoD-mediated activation of Mgn-Luc. By contrast, the ability
of HEB␣ and HEB␤ to activate Mgn-Luc transcription in the
absence of MyoD was unaffected by mutation of E1 and was
increased upon deletion of E2. Furthermore, HEB␤ and, more
strikingly, HEB␣ displayed dramatically increased activity on
the double E-box mutant reporter vector (Mgn-LucE1mut/
⌬E2). Interestingly, each canonical E-box is flanked by a noncanonical E-box. Importantly, Berkes and colleagues demonstrate that in vitro-translated MyoD and E12 are able to bind
to the noncanonical E-boxes (5). This suggests that HEB␣ and
HEB␤ are able to bind to the noncanonical E-boxes in the
myogenin promoter. Moreover, the data also indicate that the
canonical E-boxes, E1 and E2, function in two ways—activating myogenin transcription in the presence of MyoD and precluding activation of the myogenin promoter in the absence of
MyoD.
As previously described, synergy reflects the ability of two
transcription factors to function cooperatively as a complex. A
synergy value of 1 indicates that the two factors function independently, and a value greater than 1 is indicative of cooperation. However, a value less than 1 reflects active repression of
the complex. This may involve repression of a complex that is
bound to DNA or inhibition of DNA binding. Simply inhibiting
the formation of the active complex without affecting DNA
binding of each individual factor would result in independent
activity (synergy ⫽ 1).
In the absence of the E1 E-box, HEB␣ and HEB␤ functioned as repressors of MyoD activity on the myogenin promoter, as evidenced by synergy values of less than 1 (Fig. 5C).
Importantly, MyoD-HEB␤ synergy was more dramatically reduced than MyoD-HEB␣ synergy. In contrast, deletion of the
E2 E-box resulted in a robust twofold increase in synergy
between MyoD and HEB␤ (Fig. 5C). Both HEB␣ and HEB␤
were unable to function synergistically with MyoD to activate
Mgn-LucE1mut/⌬E2 (Fig. 5C). We interpret these data to suggest that, during initiation of differentiation, a transcriptionally
active MyoD-HEB␤ complex binds the E1 E-box to stimulate
myogenin transcription. Furthermore, the increase in synergy
in the absence of the E2 E-box suggests that an unidentified
complex, bound to the E2 E-box, negatively regulates the activity of the E1 E-box.
MEK1 specifically inhibits the MyoD-HEB␣ complex. There
are a number of defined functional domains within MyoD,
including a DNA binding domain (amino acids 102 to 162), a
transcriptional activation domain (amino acids 3 to 56), and
chromatin remodeling domains (amino acids 63 to 99 and 218
to 269) (12, 15, 49). Deletion of amino acids 3 to 56 (MyoD⌬356) or 63 to 99 (MyoD⌬63-99) abolishes transcriptional activity
on a transiently transfected reporter vector and negatively impacts expression of a particular subset of MyoD-regulated
genes (5, 49, 56; data not shown). Importantly, mutation of
amino acids 96 and 98 (MyoD-W96A/C98A) or serine 253
(MyoD-S253P) alters the expression of a subset of genes distinct from that of MyoD⌬3-56 (5). Specifically, full activation
of myogenin expression requires these amino acids (Trp96,
Cys98, and Ser253), yet these amino acids are not required for
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expression of muscle creatine kinase, a gene induced later in
myogenic differentiation (5). To investigate if specific regions
within either the N or C terminus are required for HEBmediated synergistic activation of MyoD, deletion mutants of
MyoD were cotransfected with either HEB␣ or HEB␤ and
Mgn-Luc.
Strikingly, the transcriptional activity of MyoD⌬63-99 was
not increased by coexpression of HEB␣ or HEB␤ and was
unable to be synergistically activated by either isoform of HEB
(Fig. 6A). This domain is implicated in maintaining stable
binding of MyoD to the myogenin promoter by mediating the
formation of a complex with the homeobox-containing protein
Pbx1 (5). Our data suggest that amino acids 63 to 99 are also
required for HEB␤ to synergize with MyoD and activate the
myogenin promoter. Conversely, the activity of the myogenin
promoter in the presence of MyoD⌬3-56 and HEB␤ is 10-fold
higher than in the presence of MyoD⌬3-56 alone. Moreover,
MyoD lacking amino acids 3 to 56 (MyoD⌬3-56) was fourfold
more responsive to HEB␤ than wild-type MyoD, indicating
that this region is responsible for negatively regulating the
synergistic activity of the MyoD-HEB␤ complex (Fig. 6A).
We have previously demonstrated that MyoD lacking
amino acids 3 to 56 (MyoD⌬3-56) is unresponsive to MEK1mediated repression of MyoD activity, whereas deletion of
amino acids 170 to 209 (MyoD⌬170-209) has no effect (43).
Moreover, expression of MyoD lacking amino acids 3 to 56
inhibits formation of a MyoD-MEK1 and HEB-MEK1 complex. However, the antibody that recognizes HEB is unable to
distinguish between ␣ and ␤ isoforms. If deletion of amino
acids 3 to 56 increases MyoD-HEB␤ synergy and this region is
important for MEK1-mediated repression of MyoD activity,
then does MEK1 inhibit MyoD-HEB␤ synergy?
An activated form of MEK1 (ActMEK1) was cotransfected
with MyoD, MyoD⌬3-56, or MyoD⌬170-209 in addition to
HEB␣ or HEB␤ and Mgn-Luc (Fig. 6B and C). ActMEK1
dramatically reduced synergy of the MyoD-HEB␣ complex to
a value less than 1, yet it had no effect on a complex containing
MyoD⌬3-56 and a modest effect on a complex containing
MyoD⌬170-209 (Fig. 6C). This indicates that ActMEK1 actively represses the MyoD-HEB␣ complex, and this repression
requires amino acids 3 to 56. Activated MEK1 also reduced
synergy of the MyoD-HEB␤ complex, but it did so to a value
close to 1, indicating that the two transcription factors were
functioning independently in the presence of activated MEK1
(Fig. 6D). Although it is possible that MEK1 inhibits formation
of an active complex containing MyoD and HEB␤, the data
also suggest that activated MEK1 represses a MyoD-HEB␣
complex specifically. This is consistent with the fact that activated MEK1 is present during myoblast proliferation, at which
point HEB␣, but not HEB␤, is expressed (43) (Fig. 1).
Knockdown of HEB␤ inhibits differentiation. Our experiments indicate that, during initiation of myogenic differentiation, MyoD and HEB␤ synergistically activate myogenin transcription. These data therefore suggest that induction of
HEB␤ in myoblasts acts as a switch that permits progression
through the immediate early differentiation program. To investigate the effect of loss of HEB expression on myogenic differentiation, C2C12 myoblasts were transfected with siRNAs designed
specifically for HEB (no. 15, 36, 67, and 60; see Materials and
Methods for specific sequences) and assessed for myogenin
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FIG. 6. MEK1 specifically inhibits the MyoD-HEB␣ complex.
(A) 10T1/2 fibroblasts were transfected with the Mgn-Luc reporter
vector, plasmids expressing either full-length (FL) MyoD or deletion
mutants of MyoD in addition to HEB␣ or HEB␤. The bars represent
the mean synergy values, and the error bars represent standard errors
of the means (n ⫽ 8).The green horizontal line represents the value at
which the two effectors function independently or additively. (B) The
same transfection as for panel A but including either empty vector or
plasmid expressing activated MEK1. The bars represent the mean
synergy values, and the error bars represent standard errors of the
means (n ⫽ 8). The green horizontal line represents the value at which
MyoD and HEB␣ function independently or additively. (C) The same
transfection as for panel B but with HEB␤ instead of HEB␣.

expression 48 h after stimulation with differentiation medium
(Fig. 7). Typically, transient transfection resulted in about 10 to
12% of cells transfected, as judged by Cy3-labeled siRNA
uptake.
Transfection of GAPDH-specific siRNA effectively inhibited expression of GAPDH protein as demonstrated by Western blot analysis (Fig. 7A). This indicated that a dramatically

FIG. 7. Knockdown of HEB expression inhibits induction of myogenin and differentiation. (A) Western analysis of C2C12 myoblasts transfected with
GAPDH siRNA. Note the reduced levels of GAPDH protein only in cells transfected with siRNA specific for GAPDH. The expression of tubulin was
monitored as a control for protein quantitation. (B) Western analysis of C2C12 cells transfected with HEB-specific siRNAs and then induced to
differentiate for 48 h. Note the reduced level of HEB and myogenin protein present in cells transfected with siRNAs specific for HEB␣/␤ (no. 35, mix)
and HEB␤ (no. 60). HEB siRNA no. 15 did not reduce HEB expression. (C and D) Immunofluorescent detection of myogenin and MyHC in
siRNA-transfected C2C12 cells. Cells were fixed either after 48 h of differentiation for detection of myogenin (C) or after 96 h for detection of MyHC
(D). Nuclei were counterstained with DAPI. Note the inhibition in myogenin induction (C) and delayed formation of multinucleated myotubes (D) after
HEB␣/␤ (no. 36) and HEB␤ (no. 60) induced knockdown of HEB expression. (E) Quantitation of the results in panel C. The bars represent the average
percentages of cells positive for both myogenin and siRNA (Cy3) per field of view (magnification, ⫻10). The error bars represent standard deviations
(n ⫽ 4 fields). (F) Quantitation of the results in panel D. The bars represent the average number of nuclei per siRNA-positive myotubes, and the error
bars represent standard deviations (n ⫽ 25 myotubes). ␣-HEB, anti-HEB; ␣-myogenin, antimyogenin; ␣-MyoD, anti-MyoD; ␣-Myf5, anti-Myf5;
␣-GAPDH, anti-GAPDH.
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higher percentage of cells was transfected than indicated by
Cy3 staining. This is likely due to insufficient brightness of the
fluorescent marker at a low siRNA concentration. Transfecting
a higher concentration of Cy3-labeled GAPDH- or HEB-specific siRNA produced over 90% Cy3-positive cells; however, a
number of the cells quickly detached from the plate and appeared to undergo apoptosis (data not shown).
Transfection of C2C12 myoblasts with pan-HEB-specific
siRNA no. 36 either alone or in combination with the other
HEB-specific siRNAs (mix) resulted in a high-level inhibition
of HEB expression given the overall apparent transfection
efficiency, again suggesting a higher percentage of cells transfected than indicated by Cy3 fluorescence (Fig. 7B, lanes 2 and
5). Importantly, siRNA no. 36 knockdown of HEB␣/␤ expression resulted in markedly reduced myogenin expression despite a similar level of MyoD expression compared to siRNA
no. 67 (Fig. 7B, compare lanes 2 and 3). Importantly, siRNA
no. 60, designed to specifically bind HEB␤ and not HEB␣,
inhibited myogenin expression comparable to siRNA no. 36,
consistent with the notion that MyoD and HEB␤ are required
for initiation of differentiation (Fig. 7B, compare lanes 2 and
4). Interestingly, siRNA no. 60 also induced an increase in
Myf5 expression.
Although a dramatically higher percentage of cells was
transfected than indicated by Cy3 fluorescence, cells positive
for Cy3 can be considered definitively transfected with siRNA.
The apparent transfection efficiency for each siRNA, while the
cells were still in GM, was approximately equal, with 9.8% of
cells transfected with GAPDH siRNA, 12.8% with siRNA no.
36, and 12.4% with siRNA no. 60. As demonstrated in Fig. 7C,
C2C12 cells transfected with high levels of siRNA no. 36 and
no. 60 exhibited an inability to upregulate endogenous myogenin (Fig. 7C) relative to some of the potentially untransfected
cells (Fig. 7C). By contrast, cells transfected with GAPDH
siRNA expressed normal levels of myogenin (Fig. 7C). Myogenin was expressed in 78.7% cells transfected with GAPDH
siRNA but was detected in only 24.6% of cells transfected with
HEB siRNA no. 36 and 20.5% of cells transfected with HEB␤specific siRNA no. 60 (Fig. 7E).
During the process of myogenic differentiation, myoblasts
must exit from the cell cycle and regulate expression of a large
number of genes, including transcription factors, such as myogenin, and structural proteins, such as myosin heavy chain
(MyHC) and myosin light chain (MLC). Moreover, the differentiating myoblasts must fuse to form multinucleated myotubes. After 4 days in DM, GAPDH siRNA-transfected and
untransfected C2C12 cells displayed normal differentiation kinetics, as evidenced by the presence of multiple nuclei and
MyHC expression (Fig. 7D). By contrast, cells transfected with
HEB-specific siRNAs displayed an overall delay in differentiation as judged by fusion index (Fig. 7D, arrows). For example,
GAPDH siRNA-transfected cells contained on average 5.4
nuclei per myotube, whereas cells transfected with HEB
siRNA no. 36 exhibited an average of 1.8 nuclei per myotube
(Fig. 7F). Moreover, those transfected with HEB␤-specific
siRNA no. 60 displayed an average of 1.3 nuclei per myotube.
Together, these data confirm that HEB␤ is required for the
switch from myoblast proliferation to myogenic differentiation.
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DISCUSSION
Initiation of myogenic differentiation is characterized by cell
cycle withdrawal, stimulation of MyoD transcriptional activity,
and induction of myogenin expression. Cell cycle stimulatory
molecules, such as E2F1, inhibit expression of myogenin and
prevent myogenic differentiation (11, 16, 20, 47, 52, 53). Similarly, mitogenic factors, such as fibroblast growth factor, transforming growth factor ␤, and MEK1, also negatively regulate
expression of myogenin (29, 43). Conversely, expression of
myogenin is positively regulated by insulin-like growth factor 1
(IGF-1), specifically through activation of phosphatidylinositol
3-kinase (10, 58, 59). The MEF2 family of transcription factors
also stimulate myogenin expression and myogenic differentiation, and are thought to participate in the formation of a
complex with the MRFs and their E-protein heterodimerization partners (6, 7, 36, 39, 40, 44, 48, 51, 60).
However, this simplistic model does not account for the
possibility that each myogenic gene, or group of genes, may be
regulated distinctively. Recent studies have shown that MyoD
directs multiple subprograms of gene expression, each of which
is uniquely regulated (3). For example, activation of a subset of
late-activated MyoD target genes requires p38 mitogen-activate protein kinase, whereas expression of an early target,
myogenin, requires formation of a MyoD-Pbx1 complex (5,
42). Genes expressed early in differentiation, such as myogenin, are induced primarily by MyoD (8). In contrast, MyoD
initiates regional histone modification at late-expressed targets, such as MyHC and MLC; however, full expression requires myogenin transcriptional activity.
E12 and E47 have been proposed to function as the E-protein heterodimerization partners for the MRFs, thereby enhancing activation of muscle-specific genes (28). Our experiments surprisingly demonstrated that while C2C12 myoblasts
and primary myoblasts expressed E12/E47 mRNA, the level of
E2A protein was below the limit of detection by Western and
ChIP analysis using several commercial preparations of antibody. Furthermore, ITF-2 protein was undetectable at any
point during our myoblast differentiation time course (data not
shown). However, a recent proteomic study of C2C12 myoblast
differentiation found that ITF-2 protein was detectable beginning 6 days after initiation of differentiation, at which point
HEB protein is no longer detectable (26). We also observed a
decline in HEB protein levels 4 days after initiation of differentiation, even though the mRNAs for both HEB␣ and HEB␤
were present (Fig. 1). Taken together, this suggests that E-proteins are targeted for degradation or that translation of the
mRNA is specifically inhibited.
Notch signaling induces E47 ubiquitination and degradation
by inducing formation of an E47-CHIP complex (22, 38).
CHIP, a cochaperone protein with ubiquitin ligase activity,
promotes the association of E47 with Skp2 and Cul1, resulting
in ubiquitination of E47 and eventual degradation. CHIP is
highly expressed in skeletal muscle (2) and interacts with specific amino acids in EHD2 (E-protein homology domain) and
EHD3 (22), which are highly conserved between E-protein
family members. Specifically, 81% of amino acids in these
regions of E2A and HEB are identical, including two serines
within EHD2 and a tryptophan in EHD3, which are required
for the E2A-CHIP interaction. This suggests that HEB and
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E2A may share similar mechanisms of targeted protein degradation. However, the 24-amino acid insert specific to HEB␤,
not found in HEB␣ or other E-protein family members, lies 18
amino acids C-terminal of EHD3, introducing the possibility
that this domain may interfere with the CHIP interaction and
targeted degradation of HEB␤ specifically.
Moreover, E2A degradation is induced by interaction of
amino acids 476 to 494 and 505 to 513 of E2A with mUbc9 (23,
25, 30), a ubiquitin-conjugating enzyme also expressed in skeletal muscle (17, 19). Deletion of amino acids 476 to 494 or 505
to 413 dramatically stabilizes E2A protein. Importantly, this
region of E2A is not conserved within HEB—only 5 of the 28
amino acids in the corresponding region of HEB are identical
to those of E2A, even though amino acids N-terminal and
C-terminal to this region are highly conserved between the two
E-proteins. Therefore, it is possible that HEB and E2A protein
stability is regulated by distinct mechanisms, causing E2A degradation and allowing HEB protein stability within the same
cell.
In C2C12 myoblasts and 10T1/2 fibroblasts expressing
MyoD or Myf5, neither E2A (E12 or E47) nor ITF-2 (ITF-2A
or ITF-2B) augmented the activity of MLC-Luc or 4R-Luc
(data not shown). By contrast, HEB is abundantly expressed in
primary and C2C12 myoblasts and synergistically enhances
MyoD and myogenin activity on MLC-Luc and Mgn-Luc (Fig.
3) (9, 43). Taken together, these data provide a compelling
argument that, in myoblasts and early differentiation, HEB
serves as the E-protein partner of the MRFs.
Determining the precise role of HEB in myogenic gene
transcription is complicated by the presence of two isoforms,
HEB␣ and HEB␤. Our experiments indicate that differentiation-dependent alternative splicing of HEB plays a hitherto
unappreciated regulatory role during myogenic differentiation.
While HEB␣ is expressed in both proliferating and differentiating myoblasts, HEB␤ expression is upregulated exclusively
during myogenic differentiation (Fig. 1B). Knockdown experiments demonstrated that HEB␤ is essential for myogenin
expression and differentiation into multinucleate myotubes.
Loss of HEB did not appear to completely inhibit expression of
myosin heavy chain but did alter differentiation, as the average
number of nuclei per myotube is considerably reduced in cells
positive for HEB siRNA. Moreover, cells transfected with
HEB␤-specific siRNA displayed a higher level of Myf5 expression (Fig. 7, lane 4). This is reminiscent of primary myoblasts
lacking MyoD, which express more Myf5 and remain primarily
mononuclear after mitogen withdrawal (46). Taken together,
this suggests that, in the absence of HEB␤, the transcriptional
activity of MyoD is markedly reduced. Therefore, restricted
expression of HEB␤, which governs formation of a MyoDHEB␤ complex, serves as an important means of regulating
myogenin expression.
Mice lacking HEB␣ and HEB␤ die perinatally, surviving no
longer than 2 weeks after birth (61). These mice display defects
in B-cell development but have yet to be analyzed specifically
for skeletal muscle development and satellite cell function. An
initial analysis of muscle structure and satellite cell function ex
vivo suggest that loss of HEB␣ and HEB␤ has profound effects
on skeletal muscle development as well as satellite cell survival,
proliferation, and differentiation (M. H. Parker and M. A.
Rudnicki, unpublished data). However, targeting of both iso-

forms by siRNA results in a reduction in the number of Cy3positive cells after induction of differentiation, suggesting that
loss of both HEB␣ and HEB␤ affects survival of differentiating
myocytes (data not shown). Targeting of HEB␤ alone does not
alter the number of Cy3-positive cells after initiation of differentiation relative to the GAPDH control, specifically implicating HEB␣ in maintaining survival after serum withdrawal.
Therefore, to accurately assess the role of HEB␤ in vivo and
thus validate our results in a murine system, a mouse lacking
only HEB␤ would need to be generated.
The ability of HEB to synergize with MyoD and myogenin
required the context of a natural promoter, as neither MyoD
nor myogenin could be synergistically activated by HEB on the
4R-Luc reporter plasmid (data not shown). Although this may
be the result of differences in core E-box sequence, it is more
likely to be indicative of the importance of the context, or the
position, of the E-box within a promoter. As such, MyoDHEB␤ complexes require the E1 E-box of Mgn-Luc to transcriptionally activate the myogenin promoter (Fig. 5). The E1
E-box is proximal to the TATA box and the initiator (Inr)
element of the promoter. Therefore, the ankyrin-like motif of
HEB␤ may play a role in recruiting the preinitiation complex
to the E1 E-box.
Although transfection of MyoD alone was able to activate
a myogenin promoter containing only the E2 E-box (MgnLucE1mut), cotransfection of either HEB␣ or HEB␤ repressed
MyoD activity on this reporter construct (Fig. 6C). Moreover,
the activity of the E1-complex was regulated through the E2complex, given that MyoD-HEB␤ synergy was enhanced approximately twofold in the absence of the E2 E-box (Fig. 6C,
Mgn-LucDE2). One interesting possibility is that HEB␣ and
HEB␤ each participate in the formation of transcriptional
complexes with distinct activities. For example, the complex
bound to the E2 E-box may be an inhibitory MyoD-HEB␣
complex, since HEB␣ is the predominant HEB isoform expressed during myoblast proliferation, and both MyoD and
HEB are able to bind the myogenin promoter in proliferating
cells, yet myogenin is not expressed (Fig. 2; also data not
shown). Upon initiation of myogenic differentiation, HEB␤ is
expressed and an active MyoD-HEB␤ complex binds to the E1
E-box to stimulate transcription of myogenin. Reporter assays
with an activated MEK1 mutant suggest that active MEK1,
present in proliferating cells, further regulates myogenin expression by forming a complex with MyoD-HEB␣ and inhibiting its activity (Fig. 6) (43).
A number of studies have demonstrated that HEB is able to
function both as an activator and a repressor on a given promoter, depending on the presence of other factors (31, 45, 54).
In particular, HEB represses activation of the GAP-43 gene in
PC12 cells, pending expression of Nex1/MATH2, a member of
the neuroD family of bHLH factors (50). Nex1/MATH2 binds
to the GAP-43 promoter, alleviates HEB-mediated repression,
and activates expression of the gene, resulting in neurite outgrowth and neuronal differentiation. Although the authors do
not discriminate between HEB␣ and HEB␤, it is interesting to
hypothesize that alleviating the repression may involve a switch
from a HEB␣-specific complex to a HEB␤-specific complex or
vice versa.
The E2 E-box may also bind myogenin to maintain expression of the gene. MyoD and myogenin bind to distinct portions
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of the MLC enhancer and function cooperatively to fully activate transcription of MLC (1). As such, HEB␣ or HEB␤ may
utilize this E-box in association with myogenin in later differentiation to sustain expression of myogenin. During later stages of
myogenic differentiation, both HEB␣ and HEB␤ activated the
myogenin promoter synergistically and specifically with myogenin (Fig. 3). This observation is consistent with the notion that
MyoD plays a central role in regulating the switch from myoblast proliferation to initiation of differentiation. By contrast,
myogenin functions to enforce terminal differentiation by enhancing transcriptional activity of differentiation-specific target
genes (4, 8). Therefore, MyoD initiates expression of myogenic
genes, but once myogenin is expressed, the two MRFs function
cooperatively and synergistically with HEB to fully activate
transcription.
The ability of HEB to activate Mgn-LucE1mut⌬E2, which
contains no canonical E-box, is intriguing. It strongly suggests
that, in the absence of MyoD, HEB binds a noncanonical
E-box to activate the myogenin promoter. This is consistent
with data demonstrating that in vitro-translated MyoD and
E12 bind to the noncanonical E-box adjacent to the canonical
E2 E-box (5). Berkes and colleagues further assert that MyoD,
in complex with Pbx1/Meis1, is able to activate the myogenin
promoter lacking E1 and E2 through this noncanonical E-box.
These data raise the possibility that HEB and MyoD do not
form heterodimers on E-boxes but rather participate in the
formation of a larger complex, which depends on the presence
of sequences surrounding the E-box. This hypothesis is further
supported by data that demonstrated that HEB was unable to
synergistically activate the MRFs on multimerized canonical
E-boxes (4R-Luc) (data not shown).
Therefore, HEB plays an important role in the formation of
promoter-specific complexes on muscle-specific genes. HEB␤
is expressed exclusively after initiation of differentiation in
myoblasts and specifically forms a distinct activation complex
in cooperation with MyoD to induce myogenin transcription.
This study provides the first evidence that E-proteins, specifically HEB, directly regulate the activity of the MyoD family of
bHLH transcription factors in an isoform- and promoter-specific manner. Determining the factors that regulate differentiation-specific expression of HEB␤ will be important for understanding the early aspects of myogenic differentiation.
Indeed, splicing is regulated in other tissues, such as neurons,
and the ratio of expression of HEB␣ to HEB␤ is characteristic
of each cell type. Altering the ratio in these tissues potentially
plays an essential role in the switch from proliferation to differentiation, as it does in skeletal muscle.
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